Proceedings of the 2021 GRAPPA-Collaborative Research Network (CRN) Meeting.

Q2 Medicine

The Journal of rheumatology. Supplement Pub Date : 2022-04-01 DOI:10.3899/jrheum.211336

C. Stober, I. McInnes, S. Raychaudhuri, P. Mease, S. Pennington, J. Scher, V. Chandran, A. Armstrong, M. D. de Wit, A. Cauli, D. Jadon, T. Löve, A. Ogdie, D. O'Sullivan, L. V. van Mens, C. Ritchlin, O. FitzGerald

{"title":"Proceedings of the 2021 GRAPPA-Collaborative Research Network (CRN) Meeting.","authors":"C. Stober, I. McInnes, S. Raychaudhuri, P. Mease, S. Pennington, J. Scher, V. Chandran, A. Armstrong, M. D. de Wit, A. Cauli, D. Jadon, T. Löve, A. Ogdie, D. O'Sullivan, L. V. van Mens, C. Ritchlin, O. FitzGerald","doi":"10.3899/jrheum.211336","DOIUrl":null,"url":null,"abstract":"At the 2021 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)- Collaborative Research Network (CRN) annual meeting, the GRAPPA-CRN group presented a number of project updates, including a pilot investigator-initiated study to evaluate liquid and tissue biomarkers associated with axial involvement in psoriatic arthritis (PsA). The GRAPPA-CRN session updated progress made with 3 parallel international research initiatives based on 3 previously defined unmet needs in PsA. The Health Initiatives in Psoriasis and PsOriatic arthritis ConsoRTium European States (HIPPOCRATES) is a European research consortium formed to address unmet clinical needs in PsA. The Preventing Arthritis in a Multi-Center Psoriasis At-Risk Population (PAMPA) is a US-based organization that has defined consensus terminology for preclinical phases of PsA and is interested in the transition process from psoriasis to PsA. An overview of the Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases (AMP AIM) program 2.0, a consortium including GRAPPA-CRN members that addressed these 3 unmet needs in PsA, was also presented.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of rheumatology. Supplement","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3899/jrheum.211336","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

At the 2021 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)- Collaborative Research Network (CRN) annual meeting, the GRAPPA-CRN group presented a number of project updates, including a pilot investigator-initiated study to evaluate liquid and tissue biomarkers associated with axial involvement in psoriatic arthritis (PsA). The GRAPPA-CRN session updated progress made with 3 parallel international research initiatives based on 3 previously defined unmet needs in PsA. The Health Initiatives in Psoriasis and PsOriatic arthritis ConsoRTium European States (HIPPOCRATES) is a European research consortium formed to address unmet clinical needs in PsA. The Preventing Arthritis in a Multi-Center Psoriasis At-Risk Population (PAMPA) is a US-based organization that has defined consensus terminology for preclinical phases of PsA and is interested in the transition process from psoriasis to PsA. An overview of the Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases (AMP AIM) program 2.0, a consortium including GRAPPA-CRN members that addressed these 3 unmet needs in PsA, was also presented.

查看原文本刊更多论文

2021年grappa合作研究网络(CRN)会议纪要。

在2021年银屑病和银屑病关节炎研究和评估小组(GRAPPA)-合作研究网络(CRN)年会上，GRAPPA-CRN小组提交了一些项目更新，包括一项试点研究者发起的研究，以评估与银屑病关节炎(PsA)轴向受累相关的液体和组织生物标志物。GRAPPA-CRN会议更新了基于先前定义的PsA未满足的3个需求的3个平行国际研究计划的进展。欧洲国家银屑病和银屑病关节炎健康倡议联盟(HIPPOCRATES)是一个欧洲研究联盟，旨在解决银屑病未满足的临床需求。多中心银屑病高危人群的关节炎预防(PAMPA)是一个美国组织，已经定义了PsA临床前阶段的共识术语，并对从银屑病到PsA的过渡过程感兴趣。加速药物伙伴关系自身免疫和免疫介导疾病(AMP AIM)计划2.0的概述，包括GRAPPA-CRN成员的联盟，解决了PsA中这3个未满足的需求。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

The Journal of rheumatology. Supplement Medicine-Medicine (all)

自引率

0.00%

发文量

期刊介绍： The Journal of Rheumatology is a monthly international serial edited by Duncan A. Gordon, The Journal features research articles on clinical subjects from scientists working in rheumatology and related fields, as well as proceedings of meetings as supplements to regular issues. Highlights of our 36 years serving Rheumatology include: groundbreaking and provocative editorials such as "Inverting the Pyramid," renowned Pediatric Rheumatology, proceedings of OMERACT and the Canadian Rheumatology Association, Cochrane Musculoskeletal Reviews, and supplements on emerging therapies.